Tscan Therapeutics is trading at $0.20, down 6.69%, amid likely broader risk-off pressure; no company-specific catalyst was identified. - September inflation was hotter than expected, while major U.S. indexes and the biotech sector were lower; XBI fell 2.01%. - The latest listed company release was its September 2 strategic reorganization; the Cellares agreement dates to June 3.